retatrutide spray 5ML Nasal Retatrutide Peptide | Research Peptide

The STEP 1 trial (Wilding et al., The Lancet, 2021) showed an average weight loss of 14.9% over 68 weeks versus 2.4% in the placebo group a landmark result that established semaglutide as the benchmark for GLP-1 weight loss

Women using oral contraceptives should use a non-oral method or add a barrier method during treatment due to potential decreased effectiveness, particularly for 4 weeks after any dose increase

Discrepancies in mortality-related outcomes could be due to differences in follow-up periods and study population

Wegovy uniquely carries SELECT-trial cardiovascular risk reduction data, a label most Indian generics do not yet carry

Addressing changes in facial appearance after rapid weight loss is essential for those seeking long-term confidence in their look